Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Go back to Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome| (NASDAQ: IONS) | Delayed: 54.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.01 | 52 Week High | $62.68 | |||
| Open | $54.01 | 52 Week Low | $19.59 | |||
| Day High | $54.01 | P/E | N/A | |||
| Day Low | $54.01 | EPS | $0.00 | |||
| Volume | 1,051 | |||||
